Beijing Hotgen Biotech Co

Beijing Hotgen Biotech Co Current Liabilities

The Current Liabilities of Beijing Hotgen Biotech Co (688068.SS) as of Nov 5, 2026 is 106.59 M CNY. In the previous year, Current Liabilities was 254.72 M CNY — a change of -58.15% (lower).

Current Liabilities

106.59 MCNY

YoY

-58.15%

Last updated:

Current Liabilities of Beijing Hotgen Biotech Co is 2025 106.59 M CNY. Current Liabilities of Beijing Hotgen Biotech Co was 2024 254.72 M CNY. It decreases by -58.15% lower compared to the previous year.

The Beijing Hotgen Biotech Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
61.62 M CNY
Jan 1, 2019
56.83 M CNY
Jan 1, 2020
155.04 M CNY
Jan 1, 2021
481.22 M CNY
Jan 1, 2022
670.41 M CNY
Jan 1, 2023
210.17 M CNY
Jan 1, 2024
254.72 M CNY
Jan 1, 2025
106.59 M CNY
The Beijing Hotgen Biotech Co Current Liabilities history
YEARCurrent LiabilitiesYoY
106.59 MCNY-58.15%
254.72 MCNY+21.20%
210.17 MCNY-68.65%
670.41 MCNY+39.31%
481.22 MCNY+210.39%
155.04 MCNY+172.81%
56.83 MCNY-7.77%
61.62 MCNY+87.07%
32.94 MCNY+17.94%
27.93 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beijing Hotgen Biotech Co Stock analysis

What does Beijing Hotgen Biotech Co do? Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring. Beijing Hotgen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Hotgen Biotech Co stock

Current Liabilities of Beijing Hotgen Biotech Co is 106.59 M CNY in 2025.

Current Liabilities of Beijing Hotgen Biotech Co changed from 254.72 M CNY to 106.59 M CNY, representing a -58.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Beijing Hotgen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Beijing Hotgen Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Beijing Hotgen Biotech Co

All Key Metrics — Beijing Hotgen Biotech Co